Gastric cancer is a very serious disease and is naturally resistant to many anticancer drugs. To reduce the mortality and improve the effectiveness of therapy, many studies have tried to find key biomarkers. Proteomic technologies are providing the tools needed to discover and identify disease-associating biomarkers. The proteomic study of gastric cancer establishes any specific events that lead to cancer, and it provides a direct way to define the true function of genes. Using two dimensional (2-D) electrophoresis of the stomach cancer tissue, we have gained about 1,500 spots in each gel, and 140 protein spots also were identified. Among the identified proteins, there were seven over-expressed proteins in stomach cancer tissue: NSP3, transgelin, prohibitin, heat shock protein (hsp) 27 and variant, protein disulfide isomerase A3, unnamed protein product and glucose regulated protein. There were also seven under-expressed proteins in stomach cancer: Apolipoprotein A-1, p20, nucleoside diphosphate isomerase A, alpha 1 antitrypsin, desmin, serum albumin and serotransferrin.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055082 | PMC |
| http://dx.doi.org/10.3346/jkms.2003.18.4.505 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Short-term outcomes of preoperative computed tomography angiography versus standard assessment in patients with BMI ≥ 25.0 kg/m undergoing laparoscopic gastrectomy: the GISSG20-01 randomized clinical trial.
Gastric Cancer
January 2025
Department of Gastrointestinal Surgery, Affiliated Hospital of Qingdao University, No. 16 Jiangsu Road, Qingdao, China.
Background: Laparoscopic gastrectomy lacks hand-direct tactile sense and has a limited surgical field compared to laparotomy. Apart from textbook classification, there are anatomical variations in the gastric arteries. Laparoscopic gastrectomy presents technical difficulties and necessitates a more comprehensive comprehension of regional anatomy than open surgical procedures.
View Article and Find Full Text PDFEnvironmental factors inducing gastric cancer: insights into risk and prevention strategies.
Discov Oncol
January 2025
The Second Hospital of Lanzhou University, Lanzhou, 730030, China.
Gastric cancer, a prevalent malignant tumor worldwide, poses a significant challenge to global health. Despite ongoing advancements in treatment methods, its high incidence and mortality rates remain concerning. Although progress in treating gastric cancer is encouraging, a more critical focus is on enhancing prevention efforts.
View Article and Find Full Text PDFNomogram for pre-procedural prediction of lymph node metastasis in patients with submucosal early gastric cancer.
Surg Endosc
January 2025
Department of Gastrointestinal Surgery, Northern Jiangsu People's Hospital, Clinical Teaching Hospital of Medical School, Nanjing University, 98 Nantong West Road, Yangzhou, 225001, Jiangsu, China.
Background: The treatment of early gastric cancer (EGC) is contingent upon the status of lymph node metastasis (LNM). Accurate preoperative prediction of LNM is critical for reducing unnecessary surgeries. This study seeks to evaluate the risk factors for LNM in submucosal EGC and develop a predictive model to optimize therapeutic decision-making.
View Article and Find Full Text PDFHost tissue factors predict immune surveillance and therapeutic outcomes in gastric cancer.
Cancer Immunol Res
January 2025
Memorial Sloan Kettering Cancer Center, New York, NY, United States.
The immune composition of solid tumors is typically inferred from biomarkers, such as histologic and molecular classifications, somatic mutational burden, and PD-L1 expression. However, the extent to which these biomarkers predict the immune landscape in gastric adenocarcinoma-an aggressive cancer often linked to chronic inflammation-remains poorly understood. We leveraged high-dimensional spectral cytometry to generate a comprehensive single-cell immune landscape of tumors, normal tissue, and lymph nodes from patients in the Western Hemisphere with gastric adenocarcinoma.
View Article and Find Full Text PDFConsiderations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study.
Int J Cancer
January 2025
Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
The majority of patients with advanced esophageal or gastric cancer do not start palliative systemic treatment. To gain insight into the considerations underlying the decision not to start systemic treatment, we analyzed characteristics of patients starting and not starting systemic treatment, reasons for not starting systemic treatment, and receipt of local palliative treatments on a nationwide scale. Patients diagnosed with advanced esophageal or gastric cancer between 2015 and 2021 were included (n = 10,948).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!